Evidence map›Paper›PMID 35216831›Full record

ArticleFertility and sterility2022

Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.

Beth Zhou, Brian Kwan, Milli J Desai, Vinit Nalawade, Kathryn J Ruddy, Paul C Nathan, Henry J Henk, James D Murphy, Brian W Whitcomb, H Irene Su

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fertility and sterility, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Beth ZhouDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Diego, California.
Brian KwanDivision of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California, San Diego, California; Moores Cancer Center, University of California, San Diego, California.
Milli J DesaiDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Diego, California.
Vinit NalawadeDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, California.
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.
Paul C NathanThe Hospital for Sick Children, Toronto, Ontario, Canada.
Henry J HenkOptumLabs, Eden Prarie, Minnesota.
James D MurphyDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, California.
Brian W WhitcombDepartment of Biostatistics & Epidemiology, School of Public Health & Health Sciences, University of Massachusetts, Amherst, Massachusetts.
H Irene SuDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Diego, California; Moores Cancer Center, University of California, San Diego, California. Electronic address: hisu@health.ucsd.edu.
University of California, San Diego · USHospital for Sick Children · CAMayo Clinic · USOptum (United States) · USUniversity of Massachusetts Amherst · US

Funding

TRAINING IN REPRODUCTIVE SCIENCEST32HD007203 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PAMELA L MELLON · 1988 to 2026
$4.8M
UC San Diego Clinical and Translational Research InstituteTL1TR001443 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2019
$3.4M
NCATS NIH HHS TL1 TR001443NICHD NIH HHS T32 HD007203
6 · The paper itself

Abstract

objectiveTo compare antimüllerian hormone (AMH) patterns by cancer status and treatment exposures across 6 years after incident breast cancer using administrative data.

designIn a cross-sectional design, AMH levels in patients who developed incident breast cancer between ages 15-39 years during 2005-2019 were matched 1:10 to levels in females without cancer in the OptumLabs Data Warehouse. Modeled AMH patterns were compared among cyclophosphamide-based chemotherapy, non-cyclophosphamide-based chemotherapy, no chemotherapy, and no breast cancer groups.

settingCommercially insured females in the United States. PATIENT(S): Females with and without breast cancer. EXPOSURE(S): Breast cancer, cyclophosphamide- and non-cyclophosphamide-based chemotherapy. MAIN OUTCOME MEASURE(S): AMH levels. RESULT(S): A total of 233 patients with breast cancer (mean age, 34 years; standard deviation, 3.7 years) contributed 278 AMH levels over a median of 2 years (range, 0-6.7 years) after diagnosis; 52% received cyclophosphamide-based chemotherapy, 17% received non-cyclophosphamide-based chemotherapy (80% platinum-based), and 31% received no chemotherapy. A total of 2,777 matched females without cancer contributed 2,780 AMH levels. The pattern of AMH levels differed among the 4 groups. Among females without cancer and breast cancer survivors who did not undergo chemotherapy, AMH declined linearly over time. In contrast, among those who received cyclophosphamide-based and noncyclophosphamide-based chemotherapy, a nonlinear pattern of AMH level of initial fall during chemotherapy, followed by an increase over 2-4 years, and then by a plateau over 1-2 years before a decline was observed. CONCLUSION(S): In breast cancer survivors, AMH levels from administrative data supported ovarian toxicity of non-cyclophosphamide-based chemotherapy in breast cancer and efficiently depicted the timing and duration of changes in ovarian reserve to reflect the residual reproductive lifespan.

Indexed as

Breast NeoplasmsCancer SurvivorsOvarian ReserveAdolescentAdultAnti-Mullerian HormoneCross-Sectional StudiesCyclophosphamideFemaleHumansYoung AdultAnti-Mullerian HormoneCyclophosphamideAMHbreast cancercyclophosphamideovarian reserveplatinum

Identifiers

PMID35216831
PMCPMC9081208
OpenAlexW4214554217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.